Compare DexCom, Inc. (DXCM) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Taskus Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Taskus Inc trades at $8.14 (market cap $723.41M). The key difference: DexCom, Inc. is far larger — about 44× Taskus Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Taskus Inc for 34 Days on average.
| DXCM | TASK | |
|---|---|---|
Market Cap | $31.86B | $723.41M |
Volume | 3,607,070 | 201,303 |
Sector | Health | Technology |
52-Week High | $92.34 | $14.69 |
52-Week Low | $54.84 | $4.57 |
Typical Hold Time | 62 Days | 34 Days |
Enterprise Value | $31.32B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
TaskUs (TASK) trades at $8.01, up 1.52% today, with a bearish technical signal but strong fundamentals. The company reported Q2 2026 revenue of $308.9 million, beating estimates, with net income margin improving to 8.75% in 2025. Valuation ratios appear attractive, with a P/E of 6.8 and P/S of 0.6, while analyst consensus is a Buy with a $9.33 price target. Recent news highlights AI services growth offsetting declines in other segments.
The outlook is mixed; low valuations and AI-driven revenue growth present upside, but technical bearishness and margin pressures from labor costs pose risks. Investors should weigh fundamental strength against near-term price volatility and competitive challenges in the digital services space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
